Pharma-Bio Serv (PBSV) Common Equity (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Common Equity for 17 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 8.97% year-over-year to $11.0 million; the trailing twelve-month figure through Apr 2026 stood at $11.0 million (down 8.97% YoY), and the FY2025 full-year result was $12.5 million, down 8.91% from the prior year.
• Common Equity climbed to $11.0 million in Q2 2026 per PBSV's latest filing, from $10.2 million in the prior quarter.
• Across five years, Common Equity topped out at $17.4 million in Q1 2022 and bottomed at $10.2 million in Q1 2026.
• Historically, Common Equity has averaged $14.2 million across 5 years, with a median of $14.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity sank 32.26% in 2022, then gained 0.23% in 2023.
• Over 5 years, Common Equity stood at $16.6 million in 2022, then fell by 2.6% to $16.1 million in 2023, then slipped by 14.95% to $13.7 million in 2024, then fell by 8.91% to $12.5 million in 2025, then declined by 11.67% to $11.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $11.0 million, $10.2 million, and $12.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.